Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.69 |
| ▸ | DRD4 | P21917 | 1/20 | 0.69 |
| ▸ | DRD3 | P35462 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10355675 | 0.89 | DRD3 (0.75) | DRD2DRD4DRD3 | |
| SCHEMBL10355480 | 0.89 | DRD3 (0.75) | DRD2DRD4DRD3 | |
| SCHEMBL3361739 | 0.89 | DRD3 (0.75) | DRD2DRD4DRD3 | |
| SCHEMBL9500719 | 0.89 | DRD2 (0.69) | DRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL9652364 | 0.88 | DRD2 (0.67) | DRD2DRD4DRD3 | |
| Hydrochloric Acid SCHEMBL9502355 | 0.88 | DRD2 (0.67) | DRD2DRD4DRD3 | |
| Epidepride SCHEMBL8961800 | 0.86 | DRD2 (0.81) | DRD2DRD4DRD3 | |
| Epidepride SCHEMBL8961795 | 0.86 | DRD2 (0.81) | DRD2DRD4DRD3 | |
| Epidepride SCHEMBL29521228 | 0.86 | DRD2 (0.81) | DRD2DRD4DRD3 | |
| SCHEMBL11464054 | 0.83 | DRD2 (0.77) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0317873-B1 | RADIOIODINATED BENZAMIDES AND METHOD OF THEIR USE AS RADIOIMAGING AGENTS | THE VANDERBILT UNIVERSITY (US) | 1993-05-12 | — | — | EP | claimed |
| EP-0317873-A1 | Radioiodinated benzamides and method of their use as radioimaging agents | THE VANDERBILT UNIVERSITY (US) | 1989-05-31 | — | — | EP | claimed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
| US-5446147-A | Imaging agent | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1995-08-29 | — | — | US | disclosed |
| US-5446147-A | Imaging agent | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1995-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | DRD2 59/4885DRD4 82/4885DRD3 80/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | DRD2 3870/4885DRD4 2928/4885DRD3 2912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.